- 5.1. Clinical Trial
- 5.1.1. Liver Cancer
- 5.1.2. Cholangiocarcinoma
- 5.2. Basic Research
5.0 Hepatobiliary |
||||||
|
5.1 Clinical Trial |
||||||
|
5.1.1 Liver Cancer |
||||||
|
Study Title |
Main Inclusion/Exclusion |
Investigational Product |
Principal Investigator |
Department |
|
Contact number |
|
START-FIT double IO Sequential TransArterial chemoembolization and stereotactic radiotherapy Followed by durvalumab (MEDI4736) and tremelimumab for downstaging hepatocellular carcinoma for hepatectomy. |
Key Inclusion Criteria: 1. Diagnosis of unresectable HCC.
2. No prior systemic therapy nor immunotherapy.
3. No prior trans-arterial chemo-embolization (TACE).
4. No prior radiotherapy to the liver or selective internal radiation (SIRT).
Key Exclusion Criteria: 1. Participation in another clinical study with an investigational product within 4 weeks prior to the first dose of study treatment.
2. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
3. Prior radiotherapy to the region of liver or selective internal radiotherapy. 4. History of primary immunodeficiency or allogenic organ transplantation.
5. Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
6. Active or prior documented gastrointestinal variceal bleeding. |
Transarterial Chemoembolisation (TACE) + Stereotactic Body Radiation Therapy (SBRT) + Durvalumab (Anti-PD-L1 Monoclonal Antibody) +Tremelimumab (Anti-CTLA-4 Monoclonal Antibody) |
Prof. Albert Chi-Yan Chan |
Department of Surgery |
isabelw@hku.hk |
Isabel Chan 2255 5362 |
|
Study Title |
Main Inclusion/Exclusion |
Investigational Product |
Principal Investigator |
Department |
|
Contact number |
|
(Protocol ID: AU409-LEES-2021-03): A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Hepatocellular Carcinoma Patients Who Failed Standard Treatment. |
Key Inclusion Criteria: 1. Subjects with histologically and/or cytologically confirmed advanced (unresectable or metastatic) hepatocellular carcinoma (HCC) that have failed any of standard treatment (including Immunotherapies and/or Tyrosine Kinase Inhibitor therapies, or Oxaliplatin-based systemic chemotherapies), recurrence, or are intolerant.
2. Subjects must have previously completed chemotherapy, radiotherapy, interventional therapy for more than 4 weeks.
Key Exclusion Criteria: 1. Subjects of central nervous system metastasis with clinical symptoms.
2. Allergies to any ingredients or excipients in AU409.
|
AU 409 (RNA transcription modulator) |
Dr. Chiang Chi Leung |
Department of Clinical Oncology |
cancermed@hku.hk |
2255 1661 |
|
Study Title |
Main Inclusion/Exclusion |
Investigational Product |
Principal Investigator |
Department |
|
Contact number |
|
AN4005X0101 (Protocol ID: AN4005X0101) An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors |
Key Inclusion Criteria: Cohort 3B: - Anti-PD-L1 naïve subjects with advanced unresectable or metastatic MSI-H/dMMR solid tumors, progressed from prior systemic therapy
|
AN4005X0101(anti PD-L1 mAb) |
Prof. Thomas Yau |
Centre of Cancer Medicine |
cancermed@hku.hk |
2255 1661 2255 4361 |
|
Study Title |
Main Inclusion/Exclusion |
Investigational Product |
Principal Investigator |
Department |
|
Contact number |
|
(Protocol ID: D7029C00001) A Phase III, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostimig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (Artemide-HCC01) |
Key Inclusion Criteria: 1. Confirmed locally advanced or metastatic and/or unresectable HCC based on histopathology.
2. Must not have received prior systemic therapy for HCC.
3. At least 1 measurable lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have a short axis ≥ 15 mm) with CT or MRI. A lesion which progressed after previous ablation or TACE could be measurable if it meets these criteria.
Key Exclusion Criteria: 1. Any concurrent chemotherapy, study treatment, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable. Prior treatment with anti-CTLA-4 and/or anti-TIGIT.
|
Arm A: Tremelimumab (Anti-CTLA-4 Monoclonal Antibody)+ Rilvegostimig (anti- PD-1 and Anti-TIGIT T cell monoclonal Ab) + Bevacizumab (VEGF inhibitor) Vs. Arm B: Rilvegostimig+ Bevacizumab Vs. Arm C: Atezolizumab (anti-PD-L1 monoclonal Ab) + Bevacizumab
|
Prof. Thomas Yau |
Centre of Cancer Medicine |
cancermed@hku.hk |
2255 1661 |
|
5.2.1 Basic Research |
||||
|
Study Title |
Principal Investigator |
Department |
|
Contact number |
|
A study of the regulation of TAX1 binding protein 2 by p21-activated protein kinase 4 in liver cancer metastasis |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
A study of the role of salt-inducible kinase 2 in regulating chemo-resistance of liver cancer cells |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
Characterization of the role of liver cancer stem cell marker, CD133 in promoting chromosome instability in hepatocarcinogenesis |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
Functional characterization of the roles of NIMA-related kinase, Nek2 in liver cancer development and metastasis |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
Functional characterization of the roles of Polo-like kinase 4, Plk4 in hepatocarcinogenesis |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
The therapeutic potential of Polo-like protein kinase 4 in liver cancer |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
Characterization of novel HBx regulated gene in hepatocellular carcinoma |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
A study of the role of p21-activated kinase 4 (PAK4) in chromosome instability |
Dr Yick Pang Ching |
School of Biomedical Sciences
|
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
Molecular mechanisms of Pumilio-Regulated Chromosomal Instability in Hepatocellular Carcinoma |
Dr Yick Pang Ching |
School of Biomedical Sciences
|
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
Development of a P-21 activated protein kinase 4 specific inhibitory peptide as a novel hepatocellular carcinoma therapeutic agent |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
A study of the role of transgelin-2 in hepatocarcinogenesis |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
The role of centrosomal protein CEP295 in chromosome instability and liver cancer progression |
Dr Yick Pang Ching |
School of Biomedical Sciences |
ypching@hku.hk |
Dr Yick Pang Ching 3917 9434 |
|
Delineating and translating the mechanistic determinants to improve the clinical management of liver cancer |
Dr Clive Yik Sham Chung |
School of Biomedical Sciences
|
cyschung@hku.hk |
Dr Clive Yik Sham Chung 3917 9172 |
|
Understanding Cancer Stemness in Liver Cancer - From Regulation to Translational Applications |
Prof. Oi Lin Irene Ng |
Department of Pathology |
iolng@hku.hk |
2255 2664 |
|
A Multidisciplinary Study on CD133 Liver Cancer Stem Cells: Molecular Mechanisms, Clinical Relevance and Therapeutic Implications |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
A study of the role and therapeutic potential of targeting protein tyrosine kinase 7 (PTK7) in liver cancer |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
AGPAT4: a novel metabolic driver of stemness in hepatocellular carcinoma? |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
An Immune Perspective on Exploiting Stemness as a Cancer Cell Vulnerability for the Treatment of Liver Cancer. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences
|
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Annexin A3: potential predictive factor for the efficacy of sorafenib and new therapeutic potential in hepatocellular carcinoma. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Development and applications of a driver-dependent tumor organoid biobank for translational liver cancer research. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences
|
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Development and Pre-clinical Evaluation of a Humanized ANXA3 Neutralizing Monoclonal Antibody for Hepatocellular Carcinoma Treatment. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
An immune perspective on exploiting stemness as a cancer cell vulnerability for the treatment of liver cancer (CRF). |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
PRMT6 in the control of glucose metabolic reprogramming in CD133+ liver cancer stem cells. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Establishment of a novel ANXA3 neutralizing antibody and its use, alone or in combination with sorafenib, as a potential therapeutic regimen against liver cancer. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
PRMT6 regulates ERK1/2 signal transduction in liver cancer through CRAF. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Establishment, characterization and applications of normal liver and hepatocellular carcinoma organoid cultures. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
PRMT6 binds to and methylates BAG5, BAG6, AMBRA1 and SQSTM1 to regulate autophagy in liver cancer. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
A pre-clinical study to evaluate the therapeutic efficacy of FSTL1 neutralizing antibody in combination with sorafenib for the treatment of HCC. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Molecular and mechanistic characterization of FUT1 mediated cancer stemness in a glucose restricted liver tumor microenvironment |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
A pre-clinical study to evaluate the therapeutic efficacy of PTK7 neutralizing antibody in combination with other approved chemotherapy or molecular targeted drugs for the treatment of HCC |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Molecular and mechanistic characterization of SERPINA12 mediated cancer stemness in hepatocellular carcinoma |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Molecular and mechanistic characterization of FUT2 mediated cancer stemness in hepatocellular carcinoma with PTEN loss |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Molecular and mechanistic characterization of SPINK1 mediated cancer stemness in hepatocellular carcinoma |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Functional characterization of fucosyltransferase 1 (FUT1) in promoting cancer stemness properties in hepatocellular carcinoma |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences
|
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Regulatory role of microRNA-1246 and Wnt/β-catenin pathway interaction in CD133+ liver cancer stem cells-driven hepatocellular carcinoma |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Role of PRMT6 in regulating cancer and stemness properties in hepatocellular carcinoma |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Role of protein arginine methyltransferase 6 (PRMT6) in metabolic reprogramming in hepatocellular carcinoma |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Role of the lipid metabolic regulator DGKH in driving stemness in hepatocellular carcinoma |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Significance of serine protease inhibitor Kazal-type 1 (SPINK1) in liver cancer: function, regulation and therapeutic implication |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Annexin A3 (ANXA3) as a novel therapeutic target for liver cancer |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Prom1+ tumor-propagating cells and their dynamic cellular transition during liver cancer progression |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Targeting uPAR in tumor-associated macrophages of hepatocellular carcinoma |
Dr. Rio Ryohichi Sugimura |
School of Biomedical Sciences |
rios@hku.hk |
Dr Rio Ryohichi Sugimura 3917 9269 |
|
The immune microenvironment of recurrent hepatocellular carcinoma |
Dr. Rio Ryohichi Sugimura |
School of Biomedical Sciences |
rios@hku.hk |
Dr Rio Ryohichi Sugimura 3917 9269 |
|
Exploiting stemness as a cancer cell vulnerability using hepatocellular carcinoma (HCC) as a model system |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
Using tumour mutational landscape to resolve the cellular origin of hepatocellular carcinoma at single cell level |
Dr. Jason Wing Hon Wong |
School of Biomedical Sciences |
jwhwong@hku.hk |
Dr. Jason Wing Hon Wong 3917 9187 |
|
Role of MAPK11 in liver cancer stem cells. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
|
A multidisciplinary study on hepatic cancer stem cells. |
Prof. Stephanie Kwai Yee Ma |
School of Biomedical Sciences |
stefma@hku.hk |
Prof. Stephanie Kwai Yee Ma 3917 9238 |
Swipe to view more →
Follow HKUMed